Citigroup’s Intersect ENT, Inc XENT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-2,231
Closed -$63K 6908
2022
Q1
$63K Sell
2,231
-103,990
-98% -$2.85M ﹤0.01% 4630
2021
Q4
$2.9M Sell
106,221
-241,922
-69% -$6.56M ﹤0.01% 2302
2021
Q3
$9.47M Buy
348,143
+334,492
+2,450% +$8.27M 0.01% 1449
2021
Q2
$233K Sell
13,651
-719
-5% -$13.5K ﹤0.01% 4168
2021
Q1
$299K Sell
14,370
-8,953
-38% -$207K ﹤0.01% 3786
2020
Q4
$534K Buy
23,323
+2,049
+10% +$39K ﹤0.01% 4150
2020
Q3
$347K Sell
21,274
-21,238
-50% -$385K ﹤0.01% 4170
2020
Q2
$576K Buy
42,512
+1,715
+4% +$20K ﹤0.01% 4109
2020
Q1
$484K Buy
40,797
+33,913
+493% +$752K ﹤0.01% 3900
2019
Q4
$172K Buy
6,884
+1,394
+25% +$28.2K ﹤0.01% 5314
2019
Q3
$94K Sell
5,490
-9,456
-63% -$172K ﹤0.01% 5719
2019
Q2
$340K Buy
14,946
+1,433
+11% +$38.6K ﹤0.01% 4811
2019
Q1
$435K Sell
13,513
-62,933
-82% -$1.95M ﹤0.01% 4337
2018
Q4
$2.15M Sell
76,446
-62,980
-45% -$1.84M ﹤0.01% 2595
2018
Q3
$4.01M Buy
139,426
+54,532
+64% +$1.64M ﹤0.01% 2087
2018
Q2
$3.18M Sell
84,894
-47,634
-36% -$1.87M ﹤0.01% 2258
2018
Q1
$5.21M Sell
132,528
-98,677
-43% -$3.6M ﹤0.01% 1714
2017
Q4
$7.49M Buy
231,205
+59,528
+35% +$1.79M 0.01% 1491
2017
Q3
$5.35M Buy
171,677
+70,406
+70% +$2.08M ﹤0.01% 1704
2017
Q2
$2.83M Buy
101,271
+100,193
+9,294% +$2.27M ﹤0.01% 2223
2017
Q1
$18K Sell
1,078
-24,989
-96% -$350K ﹤0.01% 6318
2016
Q4
$315K Buy
26,067
+23,425
+887% +$303K ﹤0.01% 4875
2016
Q3
$41K Sell
2,642
-444
-14% -$6.69K ﹤0.01% 5802
2016
Q2
$40K Sell
3,086
-14,169
-82% -$222K ﹤0.01% 5717
2016
Q1
$328K Buy
17,255
+9,669
+127% +$175K ﹤0.01% 4605
2015
Q4
$171K Buy
7,586
+6,945
+1,083% +$137K ﹤0.01% 4891
2015
Q3
$15K Sell
641
-1,605
-71% -$44.3K ﹤0.01% 6222
2015
Q2
$64K Sell
2,246
-1,711
-43% -$44.8K ﹤0.01% 5345
2015
Q1
$102K Sell
3,957
-23,638
-86% -$541K ﹤0.01% 5016
2014
Q4
$512K Buy
27,595
+27,391
+13,427% +$493K ﹤0.01% 3866
2014
Q3
$3K Buy
+204
New +$3.07K ﹤0.01% 6753

Citigroup's XENT Position: Q2 2022 in Review

Citigroup sold out of Intersect ENT, Inc (XENT) in Q2 2022, closing a stake of 2,231 shares — an estimated $63K sold.

Citigroup first reported a position in XENT in Q3 2014 and held it in 31 quarters. The position peaked at $9.47M in Q3 2021. 0 funds tracked by Wall St. Rank hold XENT as of Q2 2022.

  • Citigroup reported no remaining Intersect ENT, Inc position as of Q2 2022 after selling out during the quarter.
  • Citigroup sold 2,231 Intersect ENT, Inc shares in Q2 2022, an estimated $63K.
  • Citigroup first reported a position in Intersect ENT, Inc in Q3 2014 and held it in 31 quarters.
  • Citigroup's Intersect ENT, Inc position peaked at $9.47M in Q3 2021.
  • 0 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q2 2022.

Based on Citigroup's 13F filing for Q2 2022, filed 10 Aug 2022.